Research Topics
| R PerrilloSummaryAffiliation: Ochsner Clinic Foundation Country: USA Publications
| Collaborators
|
Detail Information
Publications
Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant GroupR Perrillo
Section of Gastroenterology, Ochsner Clinic, New Orleans, LA 70121, USA
Hepatology 29:1581-6. 1999..Repeat liver biopsies in 7 patients with the mutated virus were unchanged in 2, improved in 2, and worse in 3. We conclude that lamivudine is a potentially effective therapy for hepatitis B after liver transplantation...- Management of chronic hepatitis B virus infection: current perspectives for the nurse practitionerRobert Perrillo
Section of Gastroenterology and Hepatology, Ochsner Clinic Foundation, New Orleans, Louisiana 70121, USA
J Am Acad Nurse Pract 18:203-15. 2006..To address the clinical management of chronic hepatitis B virus (HBV) infection... - Chronic hepatitis B: a critical appraisal of current approaches to therapyRobert P Perrillo
Ochsner Clinic Foundation, 1514 Jefferson Highway, New Orleans, LA 70121, USA
Clin Gastroenterol Hepatol 4:233-48. 2006..Expert opinions may differ from those of practicing hepatologists and gastroenterologists. We aimed to explore this issue further after a critical review of the literature... - Therapy of hepatitis B -- viral suppression or eradication?Robert P Perrillo
Section of Gastroenterology and Hepatology, Ochsner Clinic Foundation, New Orleans, LA 70121, USA
Hepatology 43:S182-93. 2006..I will present evidence in support of the recommendation that antiviral therapy should ideally be directed toward achieving the highest rate of viral clearance with the shortest interval of treatment... - Current treatment of chronic hepatitis B: benefits and limitationsRobert P Perrillo
Section of Gastroenterology and Hepatology, Ochsner Clinic Foundation, New Orleans, Louisiana 70121, USA
Semin Liver Dis 25:20-8. 2005..The role for combination therapy remains unclear. Much has been accomplished over the past decade, but much remains to be done... - Overview of treatment of hepatitis B: key approaches and clinical challengesRobert P Perrillo
Section of Gastroenterology and Hepatology, Ochsner Clinic Foundation, New Orleans, Louisiana 70121, USA
Semin Liver Dis 24:23-9. 2004..From a theoretical perspective, a combination of pegylated interferon with one or more nucleosides could induce a higher rate of virological response. Additional studies are needed to further address these issues... - Comparison of quality of life, work productivity and medical resource utilization of peginterferon alpha 2a vs the combination of interferon alpha 2b plus ribavirin as initial treatment in patients with chronic hepatitis CR Perrillo
Division on Gastroenterology, Ochsner Clinic Foundation, New Orleans, LA 70121, USA
J Viral Hepat 11:157-65. 2004..Patients randomized to pegIFNalpha 2a had improved work productivity, less activity impairment, decreased need for prescription drugs to treat adverse effects, and better adherence to therapy... - Management of the patient with hepatitis B virus-related cirrhosisRobert P Perrillo
Section of Gastroenterology and Hepatology, Ochsner Clinic Foundation, Clinical Professor of Medicine, Tulane University School of Medicine, 1514 Jefferson Highway, New Orleans, LA 70121, USA
J Hepatol 39:S177-80. 2003 - Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virusRobert Perrillo
Ochsner Clinic Foundation, New Orleans, LA 70121, USA
Gastroenterology 126:81-90. 2004..We evaluated the efficacy and safety of adding adefovir dipivoxil to lamivudine in 135 patients with chronic hepatitis B (CHB) and YMDD mutant HBV... - Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutantsR Perrillo
Ochsner Clinic, New Orleans, LA, USA
Hepatology 32:129-34. 2000..This study provides evidence that adefovir dipivoxil can be an effective treatment for lamivudine-resistant HBV mutants as well as wild-type HBV... - Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis BRobert P Perrillo
Section of Gastroenterology and Hepatology, Ochsner Clinic Foundation, 1514 Jefferson Highway, New Orleans, LA 70121, USA
Hepatology 36:186-94. 2002..Asians and Caucasians had similar rates of response to lamivudine at comparable ALT levels... - How will we use the new antiviral agents for hepatitis B?Robert P Perrillo
Section of Gastroenterology and Hepatology, Ochsner Clinic Foundation, 1514 Jefferson Highway, New Orleans, LA 70124, USA
Curr Gastroenterol Rep 4:63-71. 2002..From a theoretical perspective, the combination of interferon with one or more nucleoside analogues may be the most effective way to treat HBV infection in many clinical situations... - Prevalence of HBV precore/core promoter variants in the United StatesChi-Jen Chu
Division of Gastroenterology, University of Michigan, Ann Arbor, MI, USA
Hepatology 38:619-28. 2003..Physicians should be aware of the existence of HBV precore and core promoter variants and the clinical condition of "HBeAg-negative chronic hepatitis.".. - Customizing the management of chronic hepatitis B virus infectionRobert G Gish
Division of Hepatology and Complex GI, Physicians Foundation, California Pacific Medical Center, 2340 Clay Street, San Francisco, CA 94115, USA
Semin Liver Dis 27:9-17. 2007..The presentation highlighted recent findings suggesting that early, profound, and sustained viral suppression improves the probability of sustained virologic response and reduces the likelihood of nucleos(t)ide resistance... - Halting the natural history of hepatitis B viral infection: a paradigm shiftRobert P Perrillo
Hepatology Division, Baylor University Medical Center, 3500 Gaston Avenue, Dallas, TX 75246, USA
Semin Liver Dis 27:3-8. 2007..A satellite symposium conducted during the 57th Annual Meeting of the AASLD in Boston, Massachusetts, presented new findings relative to the course of HBV infection... - Intramuscular hepatitis B immunoglobulin (HBIG) and nucleosides for prevention of recurrent hepatitis B following liver transplantation: comparison with other HBIG regimensRobert D Anderson
Department of Medicine, Baylor Uinversity Medical Center and the Baylor Regional Transplant Institute, Dallas, TX, USA
Clin Transplant 21:510-7. 2007..Graft loss is usually avoidable when recurrence is discovered early and aggressively treated. The IM route is preferable to IV administration due to its ease of administration and lower cost... - Comparison of clinical outcomes in chronic hepatitis B liver transplant candidates with and without hepatocellular carcinomaStephen N Wong
Division of Gastroenterology, University of Michigan, Ann Arbor, MI 48109 0362, USA
Liver Transpl 13:334-42. 2007..In conclusion, despite more advanced liver disease and a lower rate of transplantation, ITT survival of patients listed for HBV-cirrhosis was comparable to those with HBV-HCC, possibly related to beneficial effects of antiviral therapy... - Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis?Satheesh Nair
Section of Gastroenterology and Hepatology, Ochsner Clinic Foundation BH 309, 1514 Jefferson Highway, New Orleans, LA 70121, USA
Hepatology 36:150-5. 2002..However, as this study is based on patients with advanced cirrhosis, our findings need to be confirmed in a broader population of individuals with cirrhosis... - The use of HBsAg-positive organ donors: far more than meets the eye?Robert P Perrillo
Liver Transpl 11:875-7. 2005 - Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapyRobert J Fontana
Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA
Gastroenterology 123:719-27. 2002.... - Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonrespondersEugene R Schiff
Division of Hepatology, University of Miami, Jackson Medical Towers, 1500 N W 12th Avenue, Suite 1101, Miami, FL 33136, USA
J Hepatol 38:818-26. 2003..We assessed lamivudine treatment, with or without added interferon, in patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B who had failed interferon therapy previously... - Hepatitis B virus genotypes in the United States: results of a nationwide studyChi-Jen Chu
Division of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Box 0362, Ann Arbor, Michigan 48109-0362, USA
Gastroenterology 125:444-51. 2003..HBV genotypes may account for the heterogeneity in disease manifestations among patients with chronic HBV infection... 
Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis BJoseph J Y Sung
Department of Medicine and Therapeutics, Prince of Wales Hospital, Shatin, New Territories, Hong Kong, People s Republic of China
J Hepatol 48:728-35. 2008..We aimed to evaluate nucleoside/nucleotide combination therapy in treatment-naïve HBeAg-positive patients with chronic hepatitis B (CHB)...- Hepatitis B and renal transplantation: securing the sword of damoclesRobert P Perrillo
Hepatology 36:1041-5. 2002